Cemdisiran, an under-the-skin injection therapy given every three months, significantly reduced disease activity in people with generalized myasthenia gravis (gMG) after six months of treatment. That’s according to data from […] The post Cemdisiran significantly eases disease activity in gMG adults appeared first on Myasthenia Gravis News.| Myasthenia Gravis News – The Web's Daily Resource for Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News